0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Distinguishing Benign from Malignant Euadrenal Masses

Milton D. Gross, MD; Brahm Shapiro, MB, ChB, PhD; J. Antonio Bouffard, MD; Gary M. Glazer, MD; Isaac R. Francis, MD; Gary P. Wilton, MD; Frederick Khafagi, MB, BS; and L. Paul Sonda, MD
[+] Article and Author Information

Grant Support: Partial support by grants R01-CA-43300-01, NCI CA-09015, NIAMDD R01-AM-2147702 RAD, and GCRC-HEW 3 M01 RR-0042-21SI CLR from the National Institutes of Health; and the Veterans Administration Research Service and the Nuclear Medicine Research Fund of The Division of Nuclear Medicine, The University of Michigan.

Requests for Reprints: Milton D. Gross, MD, Nuclear Medicine Service (115), Veterans Administration Medical Center, 2215 Fuller Road, Ann Arbor, MI 48105.

Current Author Addresses: Dr. Gross: Nuclear Medicine Service (115), Veterans Administration Medical Center, Ann Arbor, MI 48105.

Dr. Khafagi: Department of Nuclear Medicine, Royal Brisbane Hospital, Herston, Queensland 4029, Australia.

Drs. Bouffard, Francis, and Glazer: Department of Radiology; Dr. Sonda: Department of Surgery, Division of Urology; and Dr. Shapiro: Department of Internal Medicine; The University of Michigan Medical Center, Ann Arbor, MI 48109.

Dr. Wilton: Naples Radiologists, Naples, FL 33941-8089.


© 1988 American College of PhysiciansAmerican College of Physicians


Ann Intern Med. 1988;109(8):613-618. doi:10.7326/0003-4819-109-8-613
Text Size: A A A

Study Objective: To determine the efficacy of 131I-6-beta-iodomethylnorcholesterol (NP-59) adrenal scintigraphy in distinguishing benign from malignant euadrenal masses.

Design: Case series of patients with incidentally discovered unilateral, euadrenal masses.

Setting: Referral-based nuclear medicine clinics at university and affiliated Veterans Administration medical centers.

Patients: Consecutive sample of 119 euadrenal patients with unilateral adrenal masses discovered on computed tomographic (CT) scans for reasons other than suspected adrenal disease.

Interventions: Adrenal scintiscans done using 1 mCi of NP-59 intravenously, and gamma camera imaging, 5 to 7 days later.

Measurements and Main Results: Mean lesion diameter was 3.3 ± 1.9 cm (SD) (95% CI: 2.9 to 3.6 cm). In 76 patients, NP-59 uptake lateralized to the abnormal adrenal seen on CT scans (concordant imaging), and in all of these patients, a diagnosis of adenoma was made by needle-aspiration biopsy, adrenalectomy, or extended follow-up with repeat CT scans that were unchanged at 6 months or later. Twenty-six patients had absent or markedly reduced NP-59 uptake in the glands identified as abnormal on CT scans (discordant imaging). These adrenal masses proved to be metastatic malignancies in 19 patients, primary adrenal neoplasms other than adenoma in 4, and adrenal cysts in 3. Bilateral, symmetric accumulation of NP-59 was seen in 17 patients, in whom the adrenal masses were shown to be metastatic malignancies in 2, and adenomas in 6 (the lesions in these cases being 2 cm or less in diameter), and lesions not truly involving the adrenal in the rest (periadrenal metastases in 4 and pseudoadrenal masses in 5). Sensitivity was 76% (26 of 34 patients; CI, 58% to 88%); specificity, 100% (85 of 85 patients; CI, 95% to 100%), and accuracy, 93% (111 of 119 patients; CI, 88% to 98%).

Conclusions: Functional NP-59 scintigraphy can be used to accurately and noninvasively characterize many euadrenal masses; concordance of CT and NP-59 scans can be used to exclude the presence of a malignancy or other space-occupying adrenal lesion.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)